{
    "clinical_study": {
        "@rank": "166614", 
        "acronym": "POMEcardio", 
        "arm_group": [
            {
                "arm_group_label": "Pomegranate extract", 
                "arm_group_type": "Experimental", 
                "description": "Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.\nGroup A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.\nGroup A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators objective is to carry out a placebo-controlled, dose-response, randomized\n      clinical trial to assess the effects of polyphenols or derived metabolites on cardiovascular\n      disease risk in overweight adult subjects upon the consumption of pomegranate extract.\n\n      The investigators hypothesis is that chronic consumption of a ellagitannin-rich source such\n      as pomegranate extract could decrease serum oxidized-LDL as well as other inflammatory\n      markers. The correlation between the effect exerted and the subjects' microbiota (capacity\n      to produce the ellagitannin-derived metabolites urolithins) will indicate a possible role of\n      urolithins on the effects."
        }, 
        "brief_title": "Effect of a Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Overweight", 
        "condition_browse": {
            "mesh_term": "Overweight"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 40-65 years\n\n          -  Body mass index (BMI) >27 kg/m2\n\n          -  Healthy status (no illness in the previous 3-months).\n\n        Exclusion Criteria:\n\n          -  Smoking.\n\n          -  Pregnancy/lactation.\n\n          -  Severe medical illness/chronic disease/ or gastrointestinal pathology (ulcers,\n             irritable bowel syndrome, ulcerative colitis, Crohn disease etc.).\n\n          -  Previous gastrointestinal surgery\n\n          -  Recent use of antibiotics (within 1-month prior to the study)\n\n          -  Suspected hypersensitivity to pomegranate or any of its components\n\n          -  Consumption of nutraceuticals, botanical extracts or other vitamin supplements or\n             taking medication.\n\n          -  Regular consumption of ellagitannin-containing foodstuffs (walnuts, pomegranate,\n             strawberries, raspberries, oak-aged red wine) (after filling a food-frequency\n             questionnaire).\n\n          -  Intake of ellagitannins-containing foodstuffs the week before the pharmacokinetic\n             intervention."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061098", 
            "org_study_id": "CEBAS-CSIC-4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pomegranate extract", 
                "description": "Group A will consume 1 daily capsule of pomegranate extract for 3 weeks", 
                "intervention_name": "Pomegranate extract-first dose-Group A", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group A consumes pomegranate extract (first dose)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Group B will consume 1 daily capsules of placebo for 3 weeks.", 
                "intervention_name": "Placebo-first dose-Group B", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group B consumes placebo (first dose)"
            }, 
            {
                "arm_group_label": "Pomegranate extract", 
                "description": "After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.", 
                "intervention_name": "Pomegranate extract-first dose-Group B", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group B consumes pomegranate extract (first dose)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.", 
                "intervention_name": "Placebo-first dose-Group A", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group A consumes placebo (first dose)"
            }, 
            {
                "arm_group_label": "Pomegranate extract", 
                "description": "After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.", 
                "intervention_name": "Pomegranate extract-second dose-Group A", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group A consumes pomegranate extract (second dose)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.", 
                "intervention_name": "Placebo-second dose-Group B", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group B consumes placebo (second dose)"
            }, 
            {
                "arm_group_label": "Pomegranate extract", 
                "description": "After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.", 
                "intervention_name": "Pomegranate extract-second dose-Group B", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group B consumes pomegranate extract (second dose)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.", 
                "intervention_name": "Placebo-second dose-Group A", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Group A consumes placebo (second dose)"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pomegranate", 
            "Cardiovascular", 
            "Urolithins", 
            "Microbiota", 
            "Polyphenols", 
            "Nutraceutical", 
            "Dietary supplement"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Murcia", 
                    "country": "Spain", 
                    "zip": "30107"
                }, 
                "name": "UCAM (San Antonio Catholic University from Murcia)"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of an Ellagitannin Rich Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects. A Double-blind, Cross-over, Dose-response, Randomized, Placebo-controlled Trial (The POMEcardio Study)", 
        "overall_official": {
            "affiliation": "National Research Council (CEBAS-CSIC, Murcia, Spain)", 
            "last_name": "Dr. Juan Carlos Esp\u00edn, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Effect on circulating levels of oxidized particles of LDL-cholesterol", 
            "measure": "Change in serum oxidized LDL-cholesterol concentration", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061098"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Research Council, Spain", 
            "investigator_full_name": "Juan Carlos Esp\u00edn de Gea", 
            "investigator_title": "Full Research Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Effects on serum total cholesterol, LDL-cholesterol, HDL-cholesterol and apolipoproteins A1 (ApoA1), B (ApoB) and E (ApoE).", 
                "measure": "Change in serum lipids and lipoproteins levels", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks"
            }, 
            {
                "description": "Effect on soluble intercellular adhesion molecule (sICAM), soluble vascular adhesion molecule (sVCAM) and high-sensitivity C-reactive protein (hsCRP)", 
                "measure": "Change in serum sICAM, sVCAM and hsCRP", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks"
            }, 
            {
                "description": "Prebiotic effect: Change in short fatty acids, bifidobacteria, lactobacilli and other selected species in feces", 
                "measure": "Change in fecal microbiota", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks"
            }, 
            {
                "description": "Change in markers involved in hepatic and renal functions: GGT, AST, ALP, ALT, CPK, urate, creatinin, albumin, bilirubin, LDH.\nChange in hematological variables: leucocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, hemoglobin, hematocrit, mean corpuscular volume, mean platelet volume, platelets, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration.\nIntolerance, dyspepsia, allergic reactions, constipation, diarrhea, abdominal pain, nausea.", 
                "measure": "Number of volunteers with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks"
            }, 
            {
                "description": "Dose-response effect of pomegranate intake on phenolics and gut-microbiota derived metabolites in plasma, feces and urine.", 
                "measure": "Change in phenolics and derived metabolites in plasma, feces and urine.", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks"
            }
        ], 
        "source": "National Research Council, Spain", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Universidad Cat\u00f3lica San Antonio de Murcia", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "TUB\u0130TAK Marmara Research Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Research Council, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}